The drug showed exciting signs in the initial stages but failed to reach its targeted goal in the end.
2019 seems to be a tough year for Alzheimer’s researchers at the pharmaceutical company Biogen announced that they will be discontinuing the final stage human trial for their most awaited drug. The company said they have decided to discontinue two global Phase III trials of aducanumab. After the futility analysis that was conducted by an independent monitoring committee, they found the drug to be ineffective. It not only has shocked the Alzheimer’s researchers but it also has brought down Biogen’s shares more than 29%.
In its initial stages, the drug showed promising signs showing antibody effectively and safely, improved cognitive symptoms and cleared amyloid plaques from the Alzheimer’s patient. However, the company decided to discontinue it based on the recommendation of the independent monitoring committee. It is said that the drug is showing no further improvement and will not meet the primary endpoints of the test. According to the CEO of Biogen, Michel Vounatos, the failure in developing this drug proves its complexity and the researchers need advanced knowledge in neuroscience. This news was damning as in recent times, pharmaceutical giants Roche announced that it is stopping the major human trials on the drug called crenezumab.
And now with an announcement from Biogen, it looks really tough for this industry. The basic premise behind the research is the amyloid hypothesis which says the accumulation of Aβ in the brain is the primary influence pushing AD pathogenesis. According to some researchers, this hypothesis is entirely wrong while some say the different stages of Alzheimer’s make the research difficult. Although new research has been a failure, it has inspired lots of researchers to investigate the raft of potential causes for Alzheimer’s disease.
Subscribe to our newsletter to get notification about new updates,information, discount, etc..